Blue Jet Healthcare Limited (BLUEJET) AI Stock Analysis

• Market Cap: ₹72.41B
• Dividend Yield: 0.22%
• Average Volume (3M): 19.19K
• Price to Earnings (P/E): 20.5
• Beta (1Y): 0.98
• Revenue Growth: 63.34%
• EPS Growth: 109.89%
• Country: IN
• Employees: 447
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.00
• Shares Outstanding: 173,465,420
• 10 Day Avg. Volume: 15,409
• 30 Day Avg. Volume: 19,187
• PEG Ratio: 0.55
• Price to Book (P/B): 12.87
• Price to Sales (P/S): 14.16
• P/FCF Ratio: -427.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹600.00
• Price Target Upside: -8.18% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹443.00 ▼(-32.21% Downside)

The score is driven primarily by strong fundamentals (rapid revenue growth, high profitability, and minimal leverage), partially offset by weak cash flow quality (negative free cash flow). Technically, the stock is in a pronounced downtrend with bearish momentum, which meaningfully drags the overall score; valuation is moderate with limited dividend support.

Positive Factors

Strong revenue growth

Sustained double‑digit top‑line expansion reflects rising demand for Blue Jet's APIs and successful commercialization of products. Over 2–6 months, this growth supports scale benefits, stronger customer relationships, and reinvestment capacity to fund pipeline and capacity expansion.

High and improving margins

Elevated gross and operating margins imply durable cost advantages and pricing power, especially in specialty API niches. Margin strength supports internal funding for R&D and capex, making earnings more resilient versus cyclical input cost swings over the medium term.

Very strong balance sheet and high ROE

Extremely low leverage and a high equity base provide financial flexibility to pursue organic growth or selective M&A without refinancing stress. A high ROE signals efficient capital allocation, supporting sustainable returns and lower solvency risk over time.

Negative Factors

Deteriorating free cash flow

Negative free cash flow despite profitability indicates capital intensity or working capital strain. Persistently weak FCF can constrain reinvestment, limit balance sheet optionality, and increase reliance on external financing, risking slower long‑term growth if not remediated.

Low cash conversion efficiency

A low OCF-to-net income ratio shows earnings are not translating into cash, often due to receivables, inventory buildup, or timing. Over months this weakens liquidity, raises working capital needs, and can pressure margins or force higher borrowing during growth phases.

Limited customer disclosure / concentration risk

Revenue is B2B and driven by contract manufacturing, yet the lack of disclosed major‑customer detail raises potential concentration and renewal risk. Over time, customer dependence could amplify revenue volatility and negotiating leverage for large buyers.

Blue Jet Healthcare Limited Business Overview & Revenue Model

Company Description

Blue Jet Healthcare Limited (BLUEJET) is a dynamic player in the healthcare sector, focusing on the development and distribution of innovative medical products and services. The company operates primarily in the pharmaceuticals and medical devices sectors, offering a wide range of healthcare solutions designed to enhance patient care and operational efficiency in healthcare facilities. Core products include advanced medical devices, diagnostic tools, and a portfolio of pharmaceutical products aimed at addressing various health conditions.

How the Company Makes Money

BLUEJET generates revenue through multiple streams, including the sale of pharmaceutical products and medical devices to hospitals, clinics, and healthcare providers. The company also engages in long-term contracts with healthcare institutions for the supply of essential medical supplies, which provides a stable revenue base. Additionally, BLUEJET may collaborate with research organizations and healthcare providers to develop new products, often securing funding or revenue-sharing agreements as part of these partnerships. The company's focus on innovation allows it to stay competitive in the market, driving sales through both direct product offerings and strategic partnerships.

Blue Jet Healthcare Limited Financial Statement Overview

Summary

Strong revenue growth (+45.01% YoY) and profitability (net margin 29.65%; solid EBIT/EBITDA margins) supported by a very conservative balance sheet (debt-to-equity 0.02; equity ratio 79.94%; ROE 26.93%). The main offset is weak cash conversion and a sharp deterioration in free cash flow (FCF turned negative in 2025).

Income Statement

Blue Jet Healthcare has demonstrated strong financial performance with significant growth in total revenue from ₹7,103 million in 2024 to ₹10,299 million in 2025, reflecting a robust revenue growth rate of 45.01%. The gross profit margin improved to 55.24% in 2025, indicating efficient cost management. The net profit margin also increased to 29.65%, reflecting higher profitability. EBIT and EBITDA margins are solid at 49.30% and 41.18%, respectively. Overall, the income statement shows excellent growth and profitability.

Balance Sheet

The balance sheet of Blue Jet Healthcare reveals strong financial health with a low debt-to-equity ratio of 0.02, indicating minimal leverage. The equity ratio stands at 79.94%, showcasing a high level of financial stability. Return on equity (ROE) is impressive at 26.93%, reflecting effective use of equity to generate profits. The company's significant equity base and low debt level highlight its stability and low risk.

Cash Flow

Blue Jet Healthcare's cash flow performance is mixed. The operating cash flow to net income ratio is 0.15, suggesting lower cash conversion efficiency. However, the free cash flow to net income ratio is negative due to the decrease in free cash flow from ₹669 million in 2024 to -₹341 million in 2025, indicating challenges in generating free cash flow. While the company maintains positive operating cash flow, the pressure on free cash flow presents a potential area of concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.22B	10.30B	7.10B	7.18B	6.77B	4.94B
Gross Profit	6.32B	5.69B	3.89B	2.70B	2.97B	2.47B
EBITDA	4.88B	4.24B	2.48B	2.43B	2.69B	2.15B
Net Income	3.59B	3.05B	1.64B	1.60B	1.82B	1.38B
Balance Sheet
Total Assets	0.00	14.18B	10.59B	8.62B	7.13B	5.36B
Cash, Cash Equivalents and Short-Term Investments	3.06B	3.06B	3.09B	2.55B	1.81B	979.70M
Total Debt	0.00	199.86M	16.13M	68.31M	228.39M	516.15M
Total Liabilities	-11.33B	2.84B	2.14B	1.81B	1.92B	1.96B
Stockholders Equity	11.33B	11.33B	8.45B	6.81B	5.22B	3.40B
Cash Flow
Free Cash Flow	0.00	-341.15M	669.59M	822.79M	1.21B	807.67M
Operating Cash Flow	0.00	457.65M	2.41B	1.42B	1.46B	1.30B
Investing Cash Flow	0.00	-351.83M	-2.64B	-1.47B	-760.26M	-566.48M
Financing Cash Flow	0.00	-185.57M	-19.86M	-42.33M	-561.45M	-221.90M

Blue Jet Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 653.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 653.45 is above the 20-day moving average (MA) of 472.14, above the 50-day MA of 517.24, and below the 200-day MA of 700.35, indicating a bearish trend. The MACD of -31.24 indicates Positive momentum. The RSI at 20.97 is Positive, neither overbought nor oversold. The STOCH value of 6.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.

Blue Jet Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	75 Outperform	₹54.44B	29.85	―	0.13%	14.35%	15.79%
BIOCON	63 Neutral	₹593.57B	92.32	―	0.12%	10.62%	-66.88%
BLUEJET	63 Neutral	₹72.41B	20.55	―	0.22%	63.34%	109.89%
JUBLINGREA	63 Neutral	₹101.26B	34.82	―	0.74%	3.80%	64.94%
SYNGENE	62 Neutral	₹190.87B	54.00	―	0.19%	8.57%	-2.93%
CONCORDBIO	61 Neutral	₹122.89B	37.93	―	0.80%	3.63%	-1.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%